Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine | India Science, Technology & Innovation - ISTI Portal

×

Accessibility Controls

Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine

Implementing Organization

M/s Sapigen Biologix Pvt. Ltd., Hyderabad, Telangana

Project Overview

Focused on developing Indiaâ€™s first intranasal Covid-19 vaccine and RTS, S Malaria vaccine, with a state-of-the-art facility in Bhubaneswar.

Related Research

Funding Organization

Funding Organization

Technology Development Board (TDB)

Quick Information

Thrust Areas

Medical Sciences

Focus Area

Vaccines, Healthcare

Sanction Amount

₹ â‚¹311.30 Cr (TDB assistance â‚¹100.00 Cr)

Status

Commercialisation stage

Output

Status

Commercialisation stage

TRL: Technology Readiness Level

TRL 9

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…